icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube
A phase I/II single arm study of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma

STUDY DESIGN

Prospective, multicentre, open label trial, phase II study 

CORRELATIVE STUDIES

Blood and bone marrow samples will be collected as part of the trial to assess the immunological, epigenetics and molecular profile 

TRIAL PRINCIPAL INVESTIGATOR

Associate Professor Hang Quach

TIME FRAME

2018 – 2024

SITE LOCATIONS

TBC

PARTICIPANTS

Patients with relapsed refractory multiple myeloma who have had 1 to 3 prior lines of treatment

CURRENT ENROLMENT

TBC

STATUS

Planning